Welcome To The Stem Cell Therapeutics HUB On AGORACOM

Stem Cell is a public biotechnology company focused on the development and commercialization of drug-based therapies to treat central nervous system diseases.

Free
Message: Announces Issuance of Stock Options
Reply New Message
Back To Forum List View

Announces Issuance of Stock Options

posted on Feb 25, 2009 05:03AM
February 25, 2009
Stem Cell Therapeutics Corp. Announces Issuance of Stock Options
CALGARY, ALBERTA--(Marketwire - Feb. 25, 2009) - Stem Cell Therapeutics Corp. (the "Company" or "SCT") (TSX VENTURE:SSS) announces the issuance of stock options to officers and directors of the Company. These options were issued in connection with a reduction of executive salaries and Board of Directors' fees, all effective as of January 1, 2009.

SCT has issued an aggregate of 3,840,000 stock options to the Company's officers and Board of Directors at an exercise price of C$0.10 per share. These options will expire no later than February 25, 2014 subject to applicable vesting provisions. These options were awarded in accordance with the Company's Stock Option Plan.

About Stem Cell Therapeutics Corp.: Stem Cell Therapeutics Corp. is a Canadian public biotechnology company (TSX VENTURE:SSS) focused on the development and commercialization of drug-based therapies to treat central nervous system diseases. SCT is a leader in the development of therapies that utilize drugs to stimulate a patient's own resident stem cells. The Company's programs aim to repair neurological function lost due to disease or injury. SCT's extensive patent portfolio of owned and licensed intellectual property supports the potential expansion into future clinical programs in numerous neurological diseases such as traumatic brain injury, multiple sclerosis, Huntington's disease, Alzheimer's disease, and ALS.

For further information on Stem Cell Therapeutics Corp., visit www.stemcellthera.com.
Reply New Message
Back To Forum List View
Share
Share
New Message
Please login to post a reply